Trial · NCT05019521
Results by group805
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 805
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Rate of Change From Baseline to Week 52 in the Square Root (Sqrt) of Total Geographic Atrophy (GA) Lesion Area in the Study Eye as Measured by Fundus Autofluorescence (FAF) | Danicopan 100 mg BID | 0.465 | Standard Error 0.0289 | mm/year | |
| Rate of Change From Baseline to Week 52 in the Square Root (Sqrt) of Total Geographic Atrophy (GA) Lesion Area in the Study Eye as Measured by Fundus Autofluorescence (FAF) | Danicopan 200 mg BID | 0.391 | Standard Error 0.0306 | mm/year | |
| Rate of Change From Baseline to Week 52 in the Square Root (Sqrt) of Total Geographic Atrophy (GA) Lesion Area in the Study Eye as Measured by Fundus Autofluorescence (FAF) | Danicopan 400 mg QD | 0.443 | Standard Error 0.0301 | mm/year | |
| Rate of Change From Baseline to Week 52 in the Square Root (Sqrt) of Total Geographic Atrophy (GA) Lesion Area in the Study Eye as Measured by Fundus Autofluorescence (FAF) | Placebo | 0.406 | Standard Error 0.0304 | mm/year | |
| Change From Baseline to Week 104 in the Sqrt of the Total GA Lesion Area in the Study Eye as Measured by FAF | Danicopan 100 mg BID | 0.892 | Standard Deviation 0.4545 | mm | |
| Change From Baseline to Week 104 in the Sqrt of the Total GA Lesion Area in the Study Eye as Measured by FAF | Danicopan 200 mg BID | 0.705 | Standard Deviation 0.3831 | mm | |
| Change From Baseline to Week 104 in the Sqrt of the Total GA Lesion Area in the Study Eye as Measured by FAF | Danicopan 400 mg QD | 0.859 | Standard Deviation 0.3468 | mm | |
| Change From Baseline to Week 104 in the Sqrt of the Total GA Lesion Area in the Study Eye as Measured by FAF | Placebo - Danicopan 100 mg BID | 0.668 | Standard Deviation 0.4866 | mm | |
| Change From Baseline to Week 104 in the Sqrt of the Total GA Lesion Area in the Study Eye as Measured by FAF | Placebo - Danicopan 200 mg BID | 0.585 | Standard Deviation 0.1396 | mm | |
| Change From Baseline to Week 104 in the Sqrt of the Total GA Lesion Area in the Study Eye as Measured by FAF | Placebo - Danicopan 400 mg QD | 0.787 | Standard Deviation 0.1858 | mm | |
| Change From Baseline to Week 52 and Week 104 in the Total GA Lesion Area in the Study Eye as Measured by FAF | Danicopan 100 mg BID | Change at Week 52 | 2.347 | Standard Deviation 1.2972 | mm^2 |
| Change From Baseline to Week 52 and Week 104 in the Total GA Lesion Area in the Study Eye as Measured by FAF | Danicopan 200 mg BID | Change at Week 52 | 2.044 | Standard Deviation 1.2280 | mm^2 |
| Change From Baseline to Week 52 and Week 104 in the Total GA Lesion Area in the Study Eye as Measured by FAF | Danicopan 400 mg QD | Change at Week 52 | 2.274 | Standard Deviation 1.4482 | mm^2 |
| Change From Baseline to Week 52 and Week 104 in the Total GA Lesion Area in the Study Eye as Measured by FAF | Placebo | Change at Week 52 | 2.057 | Standard Deviation 1.2016 | mm^2 |
| Change From Baseline to Week 52 and Week 104 in the Total GA Lesion Area in the Study Eye as Measured by FAF | Placebo - Danicopan 100 mg BID | Change at Week 52 | 1.887 | Standard Deviation 1.1212 | mm^2 |
| Change From Baseline to Week 52 and Week 104 in the Total GA Lesion Area in the Study Eye as Measured by FAF | Placebo - Danicopan 200 mg BID | Change at Week 52 | 1.716 | Standard Deviation 0.9095 | mm^2 |
| Change From Baseline to Week 52 and Week 104 in the Total GA Lesion Area in the Study Eye as Measured by FAF | Placebo - Danicopan 400 mg QD | Change at Week 52 | 2.553 | Standard Deviation 1.3938 | mm^2 |
| Change From Baseline to Week 52 and Week 104 in the Total GA Lesion Area in the Study Eye as Measured by FAF | Danicopan 100 mg BID | Change at Week 104 | 4.311 | Standard Deviation 2.8803 | mm^2 |
| Change From Baseline to Week 52 and Week 104 in the Total GA Lesion Area in the Study Eye as Measured by FAF | Danicopan 200 mg BID | Change at Week 104 | 3.223 | Standard Deviation 2.3784 | mm^2 |
| Change From Baseline to Week 52 and Week 104 in the Total GA Lesion Area in the Study Eye as Measured by FAF | Danicopan 400 mg QD | Change at Week 104 | 4.504 | Standard Deviation 2.1300 | mm^2 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05019521/results